NeuroPace (NASDAQ:NPCE) Price Target Cut to $12.00 by Analysts at Cantor Fitzgerald

NeuroPace (NASDAQ:NPCE – Free Report) had its target price decreased by Cantor Fitzgerald from $21.00 to $12.00 in a report released on Friday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.

NPCE has been the subject of several other reports. Weiss Ratings cut shares of NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. Wall Street Zen downgraded shares of NeuroPace from a “hold” rating to a “sell” rating in a report on Saturday. JPMorgan Chase & Co. lowered shares of NeuroPace from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $20.00 to $9.00 in a research note on Friday. KeyCorp cut their price objective on shares of NeuroPace from $18.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, HC Wainwright reduced their target price on shares of NeuroPace from $20.00 to $12.00 and set a “buy” rating for the company in a report on Monday. Five investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $14.22.

Read Our Latest Stock Analysis on NPCE

NeuroPace Stock Performance

NeuroPace stock opened at $7.56 on Friday. The stock has a 50-day moving average price of $13.21 and a 200 day moving average price of $14.75. The company has a market capitalization of $259.49 million, a price-to-earnings ratio of -13.50 and a beta of 1.98. NeuroPace has a 52 week low of $5.46 and a 52 week high of $19.60. The company has a quick ratio of 4.09, a current ratio of 5.26 and a debt-to-equity ratio of 5.15.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of NPCE. Entropy Technologies LP acquired a new position in NeuroPace in the third quarter valued at approximately $146,000. Diversified Trust Co purchased a new stake in NeuroPace in the 3rd quarter worth approximately $153,000. First Light Asset Management LLC boosted its position in NeuroPace by 16.3% in the 2nd quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock worth $45,464,000 after purchasing an additional 401,201 shares in the last quarter. Bank of America Corp DE purchased a new stake in NeuroPace in the 2nd quarter worth approximately $322,000. Finally, Man Group plc acquired a new stake in shares of NeuroPace during the 2nd quarter worth approximately $1,336,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

NeuroPace Company Profile

(Get Free Report)

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.

See Also

Analyst Recommendations for NeuroPace (NASDAQ:NPCE)

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.